Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine + epinephrine + tetracaine (commonly known as LET or L.E.T.) is a topical anesthetic formulation used primarily in emergency departments, pediatric practices, and urgent care settings. It is applied to open wounds before suturing to provide local anesthesia. LET typically consists of: - 4% lidocaine - 0.05% epinephrine (also called racepinephrine bitartrate) - 0.5% tetracaine The formulation is available as a gel or solution and is dispensed in syringes. It's applied directly to wounds using a cotton-tipped applicator with firm pressure maintained for 15-30 minutes. Lidocaine and tetracaine are topical anesthetics that block sodium ion channels involved in neuronal impulse conduction, helping to relieve pain. Epinephrine/racepinephrine controls superficial bleeding by causing vessel constriction and slows the absorption rate of the anesthetics.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + epinephrine + tetracaine.